Abstract
Introduction:. We present our real life experience of 79 patients treated with nintedanib. Objectives: To evaluate the results of a cohort of IPF patients treated with Nintedanib in different hospitals in Spain.
Methods: The collected data were: clinical, radiological, pulmonary function test and side effects related to the treatment with Nintedanib
Results: 79 patients were included, male (74.6%). At diagnosis HRCT shows UIP pattern (34 %), POSIBLE UIP pattern (34%), combination with emphysema was observed in 24 patients (30%), 28 patients underwent a surgical lung biopsy ( 35%). Pulmonary function test baseline data were (mean ± SD) FVC 79.5 % predicted (±17.61); DLCO 44.82 % predicted (±14). 6MWT distance was 446 meters (±116), initial SpO2 95% (±2.6) and final SpO2 86%(±6,8) Most treatments were started between august 2011 and june 2016, 7 patients (35%) participated in INPULSIS trials and only 2 patients switched from pirfenidone. Only 14 patients interrupt treatment (17.9%), 8 due to side effects and 6 due to progression of IPF and death, there were dose reduction in 31 patients (39%) but 21 patients (26.9%) could be re titrated to full dose. Regarding side effects 42 (53%) patients had diarrhea, 12(15%) had nausea and 20 (25%) showed weight loss. 12 patients (15%) had elevated transaminases. Acute exacerbations were recorded in 7 patients (9%)and 6 died.
Conclusions: The results of the real life experience in these cohort of IPF patients appears consistent with the data published so far in the clinical trials. Further monitoring is required to establish the efficacy and safety in clinical practice
- Copyright ©the authors 2017
